Dengue fever was considered to be virtually absent from most parts of Latin America until the late 1960s, but since then case numbers have increased and the region is now one of the most badly affected parts of the world for this mosquito-borne viral disease.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has announced that it will be expanding its dengue vaccine clinical programme in Latin America with a new multicentre study in children and adolescents in Mexico, Colombia, Honduras and Puerto Rico.
The company’s candidate vaccine has been evaluated in clinical trials (Phase I, II) in adults and children from non-endemic (US) and endemic countries (Mexico, Philippines). Sanofi Pasteur reports that a balanced immune response against all four dengue serotypes was observed after three doses, and that the vaccine appears to be well tolerated. There are ongoing clinical studies with adults and children in Mexico, Colombia, Honduras, Puerto Rico, Peru, the Philippines, Vietnam, Singapore, and Thailand.
Further details are available in a company press release.